Abstract
Aims Tau protein is a key target of interest in developing therapeutics for neurodegenerative diseases. Here, we sought to develop a method that quantifies extracellular tau protein concentrations human cerebrospinal fluid (CSF) without antibody-based enrichment strategies.
Results We demonstrate that the fit-for-purpose validated method in Alzheimer’s Disease CSF is limited to quasi quantitative measures of tau surrogate peptides. We also provide evidence that CSF total Tau measures by LC-MS are feasible in the presence of monoclonal therapeutic antibodies in human CSF.
Conclusion Our Tau LC-MS/MS method is a translational bioanalytical tool for assaying target engagement and pharmacodynamics for anti-tau antibody drug development campaigns.
Competing Interest Statement
All authors are ore were employees of AbbVie and may own AbbVie stock. AbbVie sponsored and funded the study, contributed to the design, participated in the collection, analysis, and interpretation.
Funding Statement
All authors are or were employees of AbbVie. AbbVie sponsored and funded the study, contributed to the design, participated in the collection, analysis, and interpretation of data, and in writing, reviewing, and approval of the final publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western Institutional Review Board (WIRB) www.wirb.com WIRB approval was granted to Precision Med for collection of the samples used in this study. BioIVT has also got the approval for sample collection from WIRB. Copies of the documents are on file at AbbVie.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are presented in the manuscript.
